News archive for Neuro-SysMed

From May 28th to 30th, EBV-MS Partner Paola Zaratin, along with the Italian MS Society, hosted the Annual Scientific Congress 2024. Notable attendees included EBV-MS Project Coordinator Kjell-Morten Myhr, Deputy Project Coordinator Øivind Torkildsen, and project partner Marco Salvetti from Sapienza University of Rome, all invited by the Italian MS Society, ensuring significant representation from... Read more
On Wednesday, June 5th, 2024, a productive introduction between the consortium and the Scientific Advisory Board (SAB) was conducted during a recent gathering. The meeting marked a positive commencement of the collaboration between the SAB and the members of the EBV-MS project.
On Tuesday, January 23rd, and Wednesday, January 24th, 2024, the EBV-MS project successfully held its inaugural kick-off meeting. This meeting provided an opportunity for the project team to get acquainted, share insights, and set goals. The program was structured to cover various aspects of the project, including the introduction of partners, presentation of work packages, and discussions on... Read more
Did you know that UiB coordinates a European initiative to target the cause of MS?
Honorary Doctor Alberto Ascherio led the research that demonstrated a connection between the Epstein-Barr virus and Multiple Sclerosis (MS). Here he answers five key questions about this topic.
During 2017-2019, systematic differences in high efficacy MS-treatment strategies were preferred in Oslo (cladribine) and Bergen (rituximab). Comparisons of long-term (median 4.5 years) effects from these different treatments showed a 2.7 higher risk for new MRI disease activity after four years in the cladribine group (n=132) compared to rituximab group (n=168).
The very first Neuro-SysMed Annual Symposium took place at the historic Solstrand Hotel outside of Bergen, September 25-26, 2023. The dramatic western Norway weather did not entice to stepping out into the beautiful fjord surroundings, but all the 114 participants did nevertheless enjoy social and scientific radiance indoors.
Researchers launch pioneering EU funded research initiative to uncover role of Epstein-Barr virus in multiple sclerosis, building on recent research breakthrough.
May 20 was the Clinical Trials Day, which arrives each May 20 as an opportunity for the clinical research community to pause in reflection, recognition, and admiration of all that has been accomplished thanks to clinical trials and the people behind them. The Norwegian Parkinson's Association took the opportunity to launch a short video, where Neuro-SysMed contributes with Professor Tzoulis... Read more
Get the latest news from Neuro-SysMed in our newsletters!
Professor Charalampos Tzoulis receives $300,000 (3MNOK) from the prestigious Michael J. Fox Foundation.
The regional health authorities, Helse Vest, just released their latest funding results in which 7 Neuro-SysMed projects will receive funding for a total of ~26 Million NOK. This will secure support for important clinical treatment research focusing on multiple sclerosis (MS), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and dementia.
Helse Vest, the regional health authorities, has recently announced their 2022 awards, where Kjell-Morten Myhr received the Research Award 2022 for his outstanding work on Multiple Sclerosis research.
The results of a new clinical trial, published in the peer-reviewed journal Cell Metabolism, show that oral intake of nicotinamide riboside (NR) enhances NAD-metabolism in the brain of individuals with Parkinson’s disease, and shows promise as a potential therapy.